What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Centrica PLC and Vodafone Group plc

GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) and Vodafone Group plc (LON:VOD) are the heavyweight holdings of Murray Income Trust plc (LON:MUT).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Murray Income Trust (LSE: MUT) announced its annual results last month. The board lifted the dividend by 3.4% to record 30 years of unbroken growth. At a current share price of 762p the trailing yield is 4%.

Picking great dividend shares has helped Murray Income outperform the FTSE All-Share Index over the past three, five and 10 years.

Let’s take a look at the trust’s current top three holdings: GlaxoSmithKline (LSE: GSK), Centrica (LSE: CNA) and Vodafone (LSE: VOD) (NASDAQ: VOD.US).

GlaxoSmithKline

GlaxoSmithKline (GSK) is a longstanding favourite of income investors. The UK’s top pharmaceuticals group has continued to increase its dividend despite the recent years of patent expiries and threat from generic rivals.

Free cash flow has been tight of late but GSK has a strong late-stage pipeline of new treatments, and recent agreements to sell non-core drinks brands Lucozade and Ribena, and thrombosis brands Arixtra and Fraxiparine, will bring in handy cash of £2bn.

Analysts are forecasting a 4.2% increase in the dividend for the current year, giving a 5% yield at a recent share price of 1,540p.

Centrica

Shares of Centrica, the owner of British Gas, have come under the cosh recently as a result of Ed Miliband’s proposal to break up the ‘Big Six’ utilities and cap energy bills. High-profile fund manager Neil Woodford — Centrica’s largest shareholder — has slammed the proposal as “economic vandalism”.

Now could be a good time to invest in Centrica, if you believe Labour’s proposal is unworkable on the basis that, as Woodford says: “If Centrica and SSE cannot make any money supplying electricity to the retail market then they won’t supply it. The lights will go off …”

Centrica has been a reliable dividend payer, and the recent drop in the share price has pushed up the yield. With the shares trading at 368p, and analysts forecasting a 6% rise in this year’s dividend, the prospective income is 4.7%.

Vodafone

There was big news last month with the coming to fruition of Vodafone’s long-mooted sale of its 45% interest in US company Verizon Wireless to Verizon Communications.

On announcing the sale — worth a whopping $130bn — Vodafone said “The Board …  intends to increase the total 2014 financial year dividend per share by 8% to 11p”. At a recent share price of 217p that represents a yield of 5.1%.

Such an event as the game-changing sale of Verizon Wireless inevitably leads to some uncertainty. However, as far as the dividend is concerned, Vodafone has said that after the upcoming 11p a share payout, the board “intends to grow [the dividend] annually thereafter”.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline and Vodafone.

More on Investing Articles

Investing Articles

3 market-beating international investment funds for a Stocks and Shares ISA

It always pays to look for new ways to add extra diversity to a Stocks and Shares ISA. I think…

Read more »

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Just released: April’s latest small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »